Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

PF-562271

FAK and Pyk2 inhibitor with robust antitumor activity
 
ENZ-CHM174-0005 5 mg 148.00 USD
 
ENZ-CHM174-0010 10 mg 250.00 USD
Do you need bulk/larger quantities?
 
PF-562,271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 catalytic activity with a IC50 of 1.5 and 14 nmol/l, respectively (PMID 18339875). In addition, PF-562,271 displayed robust inhibition in an inducible cell-based assay measuring phospho-FAK with an IC50 of 5 nmol/l. PF-562,271 was evaluated against multiple kinases and displays >100x selectivity against a long list of nontarget kinases. In tests, PF-562,271 inhibits FAK phosphorylation in vivo in a dose-dependent fashion with a calculated EC50 of 93 ng/ml) using injections.

Product Specification

Alternative Name:N-methyl-n-[3-[[[2-[(2-oxo-2,3-dihydro-1h-indol-5-yl)amino]-5-trifluoromethylpyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide
 
Formula:C21H20F3N7O3S
 
MW:507.5
 
CAS:717907-75-0
 
Purity:≥95% (HPLC)
 
Identity:Determined by EM-MS, NMR
 
Appearance:White powder.
 
Solubility:Soluble in DMSO (101mg/ml) or ethanol (1mg/ml).
 
Shipping:Ambient
 
Short Term Storage:+4°C
 
Long Term Storage:-20°C
 
Scientific Background:Focal Adhesion Kinase (FAK) is a protein coded by the PTK2 gene that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis.
 
ENZ-CHM174 structure
Please mouse over
ENZ-CHM174 structure

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
FAK
Pyk
By biological activity:
FAK Inhibitor
Pyk Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,